Geron Corporation (GERN)
Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments
GERN's Rytelo showed promising sales growth, with Q4'24 net product revenue increasing by 68% to $47.5M from Q3'24's $28.2M. Despite initial optimism, the market is concerned about a potential plateau in Rytelo's sales growth after only two full quarters, based on company comments. The departure of CEO John Scarlett adds uncertainty, potentially impacting investor confidence and the company's strategic direction.
Geron Corp: How Concerned Should We Be About Rytelo Sales?
Geron Corp's imetelstat, branded as Rytelo, launched in 2024 for lower-risk MDS, with promising expansion into myelofibrosis and other indications. Despite initial market enthusiasm, GERN's stock has declined, but upcoming catalysts and a strong development pipeline offer potential upside. Financially, GERN has a solid cash runway, with significant funding from a Royalty Pharma deal, supporting continued operations and growth.
Why Geron Stock Is Plummeting Today
Geron (GERN -31.43%) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m.
Geron: Rytelo's Market Share Concerns Justified As 3L Dominates Early Sales
Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new patients starts flat. Rytelo's market share in second-line LR-MDS is lower than expected due to competition from Bristol Myers Squibb's luspatercept, impacting peak sales estimates. Financial health remains solid with a strong current ratio and cash runway extending into mid-2027, supported by recent funding deals.
Geron Corporation (GERN) Q4 2024 Earnings Call Transcript
Geron Corporation (NASDAQ:GERN ) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Aron Feingold - VP of IR and Corporate Communications John Scarlett - Chairman and CEO Michelle Robertson - EVP and CFO Jim Ziegler - EVP and CCO Joseph Eid - EVP, R&D Faye Feller - EVP and CMO Conference Call Participants Peter Lawson - Barclays Tara Bancroft - TD Cowen Faisal Khurshid - Leerink Partners Greg Harrison - Scotiabank Stephen Willey - Stifel Emily Bodnar - H.C. Wainwright Kalpit Patel - B.
Geron (GERN) Reports Q4 Loss, Tops Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.09 per share a year ago.
Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch
GERN's Rytelo, approved in mid-2024, shows promising initial sales, with Q3'24 net revenues at $28.2M, and preliminary Q4'24 net revenues of $45M-$46M. Despite some market exclusivity concerns, GERN still has many years of sales ahead unencumbered by generic competition. EU approval of Rytelo for lower-risk myelodysplastic syndromes seems likely in H1'25, providing a near-term catalyst beyond updates on sales.
Geron: Positive IMpactMF Trial Could Possibly Lead To Doubling Of RYTELO Sales
Geron Corporation's RYTELO received FDA approval for Low-Risk Myelodysplastic Syndrome and is awaiting European Medicines Agency approval as well, which might help to boost sales. Geron reported $28.2 million in the first full quarter of sales of RYTELO, with projections of $45-$46 million set for Q4 2024. Geron is conducting a Phase 3 study for RYTELO targeting JAK inhibitor relapsed/refractory Myelofibrosis patients, with interim results expected by early 2026 and final results early 2027.
Geron Stock Rallies More Than 60% in a Year: Here's Why
FDA's approval of GERN's Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year.
Geron: A Strong Launch And Financial Deals Make It Attractive
Geron exceeded expectations with $28.2mn in Q1 revenue, surpassing analyst estimates and showcasing strong physician feedback and market potential for imetelstat. Analysts are bullish, with H.C. Wainwright, Leerink, and Goldman Sachs projecting significant sales growth and maintaining high price targets for Geron. Favorable funding deals with Royalty Pharma and Pharmakon Advisors provide $375mn, enhancing Geron's financial stability and supporting future commercialization efforts.
Geron: A Post Earnings And Funding Announcement Assessment
Geron Corporation's imetelstat, now branded as Rytelo, was finally approved by the FDA in June for treating lower risk myelodysplastic syndromes and has shown solid initial sales traction. The company just reported third quarter results and announced a new financing arrangement. Analyst firms are positive on the company's prospects. An updated analysis of Geron Corporation follows in the paragraphs below.
